Goranov S
Clinic of Haematology, University of Medicine, Plovdiv, Bulgaria.
Folia Med (Plovdiv). 1994;36(4):31-6.
In this study, a cohort of 109 patients with multiple myeloma were followed prospectively. Eight patients (7%) were found to have biclonal M component, an occurrence rate considerably higher than that reported in literature. Biclonal myelomas were compared with the other monoclonal variants of myeloma by a number of biologic, clinical, immunological, biochemical, roentgenological, therapeutical and prognostic parameters. Among the biclonal myeloma patients there was strong male predominance, higher frequency of patients in advanced stage of the disease, combined production of predominantly kappa light chains, hypoalbuminemia and thrombocytopenia. Their response to therapy did not differ from that of the patients with monoclonal myeloma variants. The median survival of patients with biclonal myelomas was 25 months, ranking third by shortened survival after patients with light chain and D-type myelomas.
在本研究中，对109例多发性骨髓瘤患者进行了前瞻性随访。发现8例患者（7%）存在双克隆M成分，其发生率显著高于文献报道。通过一系列生物学、临床、免疫学、生化、放射学、治疗和预后参数，将双克隆骨髓瘤与骨髓瘤的其他单克隆变体进行了比较。在双克隆骨髓瘤患者中，男性占主导，疾病晚期患者频率更高，主要联合产生κ轻链，存在低白蛋白血症和血小板减少症。他们对治疗的反应与单克隆骨髓瘤变体患者没有差异。双克隆骨髓瘤患者的中位生存期为25个月，在生存期缩短方面仅次于轻链型和D型骨髓瘤患者，排名第三。
